Hills Bank & Trust Co Sells 32 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Hills Bank & Trust Co reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,724 shares of the company’s stock after selling 32 shares during the period. Hills Bank & Trust Co’s holdings in IDEXX Laboratories were worth $957,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. International Assets Investment Management LLC grew its stake in shares of IDEXX Laboratories by 51,631.3% in the fourth quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock worth $304,075,000 after acquiring an additional 546,775 shares during the last quarter. Winslow Capital Management LLC increased its position in shares of IDEXX Laboratories by 24.9% during the third quarter. Winslow Capital Management LLC now owns 689,873 shares of the company’s stock valued at $301,661,000 after acquiring an additional 137,621 shares in the last quarter. Barclays PLC lifted its position in IDEXX Laboratories by 46.7% in the 3rd quarter. Barclays PLC now owns 248,476 shares of the company’s stock valued at $108,651,000 after acquiring an additional 79,102 shares in the last quarter. abrdn plc boosted its stake in IDEXX Laboratories by 46.5% during the 4th quarter. abrdn plc now owns 246,130 shares of the company’s stock valued at $136,614,000 after purchasing an additional 78,166 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in IDEXX Laboratories by 51.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 225,150 shares of the company’s stock worth $98,353,000 after buying an additional 76,350 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the topic of several research analyst reports. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a report on Tuesday, January 30th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Finally, Barclays cut their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $580.88.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $13.75 on Thursday, reaching $500.82. The company had a trading volume of 546,581 shares, compared to its average volume of 445,009. The firm’s 50 day moving average price is $517.91 and its 200 day moving average price is $514.15. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The stock has a market capitalization of $41.36 billion, a PE ratio of 48.48, a price-to-earnings-growth ratio of 3.78 and a beta of 1.27. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.05 earnings per share. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.05 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.